Abstract:Epilepsy Currents, Ahead of Print. Testing of Putative Antiseizure Medications in a Preclinical Dravet Syndrome Zebrafish ModelWhyte-Fagundes PA, Vance A, Carroll A, Figueroa F, Manukyan C, Baraban SC. Brain Commun. 2024;6(3):fcae135.Dravet syndrome is a severe genetic epilepsy primarily caused by de novo mutations in a voltage-activated sodium channel gene (SCN1A). Patients face life-threatening seizures that are largely resistant to available anti-seizure medications. Preclinical Dravet syndrome animal models are a valuable tool to identify candidate anti-seizure medications for these patients. Among these, scn1lab mutant zebrafish, exhibiting spontaneous seizure-like activity, are particularly amenable to large-scale drug screening. Thus far, we have screened more than 3000 drug candidates in scn1lab zebrafish mutants, identifying valproate, stiripentol, and fenfluramine e.g. Food and Drug Administration-approved drugs, with clinical application in the Dravet syndrome population. Successful phenotypic screening in scn1lab mutant zebrafish is rigorous and consists of two stages: (i) a locomotion-based assay measuring high-velocity convulsive swim behaviour and (ii) an electrophysiology-based assay, using in vivo local field potential recordings, to quantify electrographic seizure-like events. Historically, nearly 90% of drug candidates fail during translation from preclinical models to the clinic. With such a high failure rate, it becomes necessary to address issues of replication and false positive identification. Leveraging our scn1lab zebrafish assays is one approach to address these problems. Here, we curated a list of nine anti-seizure drug candidates recently identified by other groups using preclinical Dravet syndrome models: 1-Ethyl-2-benzimidazolinone, AA43279, chlorzoxazone, donepezil, lisuride, mifepristone, pargyline, soticlestat and vorinostat. First-stage locomotion-based assays in scn1lab mutant zebrafish identified only 1-Ethyl-2-benzimidazolinone, chlorzoxazone and lisuride. However, second-stage local field potential recording assays did not show significant suppression of spontaneous electrographic seizure activity for any of the nine anti-seizure drug candidates. Surprisingly, soticlestat induced frank electrographic seizure-like discharges in wild-type control zebrafish. Taken together, our results failed to replicate clear anti-seizure efficacy for these drug candidates highlighting a necessity for strict scientific standards in preclinical identification of anti-seizure medications.

Zebrafish models of candidate human epilepsy-associated genes provide evidence of hyperexcitability

Epileptic phenotypes in loss-of-function zebrafish are rescued by blocking NMDA receptor signaling

A Zebrafish-Based Platform for High-Throughput Epilepsy Modeling and Drug Screening in F0

A zebrafish-centric approach to antiepileptic drug development

Past, present and future of zebrafish in epilepsy research

Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future

Functional analysis of epilepsy-associated GABAA receptor mutations using Caenorhabditis elegans

Clemizole and trazodone are effective antiseizure treatments in a zebrafish model of STXBP1 disorder

When Non-Promising Findings Also Go From Aquarium to Bedside: The Importance of Rigorous Preclinical Analyses of ASM Candidates

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome

Functional brain imaging in larval zebrafish for characterising the effects of seizurogenic compounds acting via a range of pharmacological mechanisms

CRISPR/Cas9 in Zebrafish: an Efficient Combination for Human Genetic Diseases Modeling

Assessment of Autism Zebrafish Mutant Models Using a High-Throughput Larval Phenotyping Platform

kcnb1 loss-of-function in zebrafish causes neurodevelopmental and epileptic disorders associated with GABA dysregulation

Drosophila melanogaster as a versatile model organism to study genetic epilepsies: An overview

Genomic evidence for the suitability of Göttingen Minipigs with a rare seizure phenotype as a model for human epilepsy

Exome Sequencing of 963 Chinese Families Identifies Novel Epilepsy Candidate Genes

The Zebrafish As a Model for Human Disease

A unified genome constraint, pathogenicity, and pLoF model identifies new genes associated with epilepsy

Efficient strategies based on behavioral and electrophysiological methods for epilepsy-related gene screening in the Drosophila model

Drosophila expressing mutant human KCNT1 transgenes make an effective tool for targeted drug screening in a whole animal model of KCNT1-epilepsy